Coeptis Therapeutics Holdings Inc
COEP11.270USD
+0.660+6.22%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
58.13MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Coeptis Therapeutics Holdings Inc Unternehmen
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Coeptis Therapeutics Holdings Inc Informationen
BörsenkürzelCOEP
Name des UnternehmensCoeptis Therapeutics Holdings Inc
IPO-datumDec 17, 2020
CEOMehalick (David)
Anzahl der mitarbeiter5
WertpapierartOrdinary Share
GeschäftsjahresendeDec 17
Addresse105 Bradford Road, Suite 420
StadtWEXFORD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl15090
Telefon17249346467
Websitehttps://coeptistx.com/
BörsenkürzelCOEP
IPO-datumDec 17, 2020
CEOMehalick (David)
Führungskräfte von Coeptis Therapeutics Holdings Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, Nov 20
Aktualisiert: Thu, Nov 20
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
5.89%
Calise (Chris)
5.43%
Mehalick (David)
2.26%
Armistice Capital LLC
1.64%
Sheehy (Christine Elise)
0.88%
Andere
83.90%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
5.89%
Calise (Chris)
5.43%
Mehalick (David)
2.26%
Armistice Capital LLC
1.64%
Sheehy (Christine Elise)
0.88%
Andere
83.90%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
9.42%
Investment Advisor
6.11%
Hedge Fund
1.97%
Investment Advisor/Hedge Fund
1.13%
Andere
81.37%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
36
241.64K
3.38%
--
2025Q3
37
241.64K
3.76%
+42.71K
2025Q2
35
198.94K
3.83%
+46.67K
2025Q1
35
152.27K
2.68%
+61.98K
2024Q4
37
107.84K
11.51%
-74.49K
2024Q3
50
182.34K
16.17%
+98.47K
2024Q2
52
83.87K
26.32%
-153.34K
2024Q1
74
237.20K
33.65%
-370.03K
2023Q4
75
236.65K
31.22%
+72.09K
2023Q3
78
164.55K
39.28%
-2.06K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
50.67K
0.89%
+23.15K
+84.08%
Sep 30, 2025
Calise (Chris)
312.69K
5.5%
--
--
Dec 18, 2025
Mehalick (David)
130.07K
2.29%
--
--
Dec 18, 2025
Armistice Capital LLC
94.77K
1.67%
+94.77K
--
Sep 30, 2024
Sheehy (Christine Elise)
50.53K
0.89%
--
--
Dec 18, 2025
Yerace (Daniel Alexander)
45.53K
0.8%
--
--
Dec 18, 2025
Geode Capital Management, L.L.C.
37.38K
0.66%
+17.10K
+84.30%
Sep 30, 2025
State Street Investment Management (US)
19.87K
0.35%
+19.87K
--
Sep 30, 2025
Renaissance Technologies LLC
18.50K
0.33%
+18.50K
--
Sep 30, 2025
Yorkville Advisors Global, LP.
8.00K
0.14%
-44.72K
-84.83%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
